IncobotulinumtoxinA for Post-stroke Upper Limb Spasticity in Neutralizing Antibody-positive Patients after Botulinum Toxin Therapy: A Report of Two Cases-Reference-Cited by-同舟云学术

IncobotulinumtoxinA for Post-stroke Upper Limb Spasticity in Neutralizing Antibody-positive Patients after Botulinum Toxin Therapy: A Report of Two Cases

Published:2022 Issue:0 Volume:7 Page:n/a
ISSN:2432-1354
Container-title:Progress in Rehabilitation Medicine
language:en
Short-container-title:PRM

Author:

Masakado Yoshihisa¹,Dekundy Andrzej²,Tateishi Shohei³,Kaji Ryuji⁴

Affiliation:

1. Department of Rehabilitation Medicine, Tokai University School of Medicine, Kanagawa, Japan

2. Global Clinical Development Therapeutics, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany

3. Pharmaceutical Development Administration Department, Teijin Pharma Limited, Tokyo, Japan

4. Department of Clinical Neuroscience, Tokushima University, Tokushima, Japan

Publisher

Japanese Association of Rehabilitation Medicine

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/prm/7/0/7_20220012/_pdf

Reference14 articles.

1. 1. Bellows S, Jankovic J: Immunogenicity associated with botulinum toxin treatment. Toxins (Basel) 2019;11:491. PMID:31454941, DOI:10.3390/toxins11090491

2. 2. Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Aktas O, Hartung HP, Hefter H: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019;92:e48–e54. PMID:30464031, DOI:10.1212/WNL.0000000000006688

3. 3. Mathevon L, Declemy A, Laffont I, Perennou D: Immunogenicity induced by botulinum toxin injections for limb spasticity: a systematic review. Ann Phys Rehabil Med 2019;62:241–251. PMID:30980953, DOI:10.1016/j.rehab.2019.03.004

4. 4. Müller K, Mix E, Adib Saberi F, Dressler D, Benecke R: Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm (Vienna) 2009;116:579–585. PMID:19352590, DOI:10.1007/s00702-009-0223-z

5. 5. Carr WW, Jain N, Sublett JW: Immunogenicity of botulinum toxin formulations: potential therapeutic implications. Adv Ther 2021;38:5046–5064. PMID:34515975, DOI:10.1007/s12325-021-01882-9